Molecular Pharming for Phytopharmaceuticals: Traditional Medicinal Plants-Driven Sustainable Green Bioreactors for Affordable Therapeutics

Molecular pharming, the production of recombinant proteins and bioactive compounds in plant-based systems, has emerged as a sustainable and cost-effective alternative to conventional biopharmaceutical manufacturing platforms. The convergence of plant biotechnology with traditional medicinal plant knowledge offers a promising framework for developing phytopharmaceuticals that are both scientifically validated and globally accessible. Traditional systems such as Ayurveda, Siddha, and Unani provide a rich repository of bioactive plant resources with long-standing therapeutic use, which can inform target selection, metabolic pathway engineering, and translational research. Sustainable green bioreactor systems including whole plants, plant cell suspension cultures, and hairy root cultures serve as efficient platforms for producing recombinant biologics, vaccine antigens, antibodies, and enhanced secondary metabolites. Advances in gene delivery methods, transient expression technologies, chloroplast engineering, and metabolic pathway reconstruction have significantly improved yield, scalability, and biosafety. Compared to mammalian cell culture systems, plant-based platforms offer reduced production costs, lower contamination risks, renewable biomass utilization, and a smaller environmental footprint. Despite challenges related to glycosylation differences, regulatory harmonization, and scale-up optimization, ongoing developments in genome editing, glycoengineering, and automated bioprocess monitoring are addressing these limitations. By integrating traditional medicinal plant knowledge with modern molecular pharming and bioprocess engineering strategies, sustainable green bioreactors present a viable pathway toward affordable, safe, and globally accessible therapeutics.